Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)

References

Page 1

	Year	Citations
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial M Baum, Aman U. Budzar, J Cuzick, The Lancet Breast OncologyEarly Breast CancerMedicinePharmacologyGynecology	2002	2K
Mortality after all major types of osteoporotic fracture in men and women: an observational study The Lancet Major TypesBone DiseaseSkeletal TraumaBone HealthObservational Study	1999	1.9K
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial Jack Cuzick, Ivana Šestak, Michael Baum, The Lancet Oncology Breast OncologyOncologyAtac TrialPharmacologyAdjuvant Treatment	2010	1.7K
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer New England Journal of Medicine	2005	1.6K
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 Aron Goldhirsch, James N. Ingle, Richard D. Gelber, Annals of Oncology	2009	1.4K
Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer Richard R. Love, Richard B. Mazess, Howard S. Barden, New England Journal of Medicine	1992	1.1K
Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures Ethel S. Siris, Ya-Ting Chen, Thomas A. Abbott, Archives of Internal Medicine	2004	1.1K
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial The Lancet Oncology 100-Month AnalysisBreast OncologyMedicineAtac TrialPharmacology	2008	911
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial R. Charles Coombes, CF Snowdon, Robert Paridaens, The Lancet Tamoxifen TreatmentClinical EffectivenessMedicineClinical TrialsBreast Cancer	2007	905
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial R. Jakesz, W. Jonat, Michael Gnant, The Lancet Breast OncologyMedicinePharmacologyGynecologyAdjuvant Tamoxifen	2005	871

Page 1